Join Free
SI Premium
RSS Feeds
E-mail Alerts
Portfolio
Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Immunoprecise Antibodies Ltd
(NQ:
IPA
)
0.6250
+0.0825 (+15.21%)
Streaming Delayed Price
Updated: 3:59 PM EDT, Oct 4, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Immunoprecise Antibodies Ltd
< Previous
1
2
3
4
5
6
7
Next >
Earnings Outlook For ImmunoPrecise Antibodies
March 15, 2023
Via
Benzinga
ImmunoPrecise Antibodies’ Subsidiary Talem Therapeutics Announces a Multi-Target AI-Driven Antibody Discovery Collaboration with Libera Bio
March 15, 2023
From
ImmunoPrecise Antibodies
Via
Business Wire
IPA to Report Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2023 on March 16, 2023
March 07, 2023
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
‘Baby with the Bathwater’ Biotechs (IPA, NRXP, PRFX, LEXX, LQDI)
June 01, 2022
Via
AB Newswire
IPA Reports Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2023
December 15, 2022
From
IMMUNOPRECISE ANTIBODIES LTD.
Via
Business Wire
Earnings Scheduled For December 15, 2022
December 15, 2022
Companies Reporting Before The Bell • Trinity Biotech (NASDAQ:TRIB) is expected to report quarterly loss at $0.04 per share on revenue of $19.50 million.
Via
Benzinga
IPA’s Subsidiary BioStrand Completes Integration of 20 Million Proprietary Structural HYFTs™ and Accelerates in Silico Drug Discovery Developments
December 08, 2022
From
ImmunoPrecise Antibodies
Via
Business Wire
IPA to Report Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2023 on December 15, 2022
December 05, 2022
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For December 2, 2022
December 02, 2022
Via
Benzinga
IPA’s Subsidiary BioStrand and BriaCell Announce Artificial Intelligence Collaboration and License Agreement to Discover and Develop Anti-Cancer Antibodies
November 30, 2022
From
ImmunoPrecise Antibodies
Via
Business Wire
ImmunoPrecise Antibodies Ltd. Announces Voluntary Delisting from TSX Venture Exchange
November 22, 2022
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
IPA’s Subsidiary Talem Therapeutics Licenses Antibodies for Three OmniChicken-Derived Programs
October 12, 2022
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
NIAID Confirms IPA’s PolyTope TATX-03 Neutralizing Activity Against the Currently Spreading SARS-CoV-2 Variant BA.2.75
September 14, 2022
From
ImmunoPrecise Antibodies
Via
Business Wire
IPA Reports Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2023
September 14, 2022
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
Earnings Scheduled For September 14, 2022
September 14, 2022
Companies Reporting Before The Bell • ImmunoPrecise Antibodies (NASDAQ:IPA) is projected to report earnings for its first quarter.
Via
Benzinga
IPA to Report Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2023 on September 14, 2022
September 08, 2022
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
Live Virus Assays at Ludwig-Maximilians-Universität München Confirm PolyTope’s Efficacy Against SARS-CoV-2 Variants Including BA.5
August 29, 2022
From
ImmunoPrecise Antibodies
Via
Business Wire
ImmunoPrecise Reports Financial Results and Recent Business Highlights for Full Fiscal Year 2022
July 29, 2022
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
IPA to Report Financial Results and Recent Business Highlights for Fourth Quarter and Full Fiscal Year 2022 on July 29, 2022
July 26, 2022
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
Earnings Scheduled For July 29, 2022
July 29, 2022
Companies Reporting Before The Bell • Capital Product Partners (NASDAQ:CPLP) is expected to report quarterly earnings at $1.13 per share on revenue of $72.73 million.
Via
Benzinga
Immunity Focused Biotherapeutic Developer with a Hybrid of Services and Technology for a Wide Range of Applications: ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA)
July 07, 2022
Via
Get News
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Histopathology Data of Preclinical Repeated Dose Toxicity Study and ex vivo Human Tissue Cross-Reactivity (TCR) Analysis Support Safety of IPA’s PolyTope® TATX-03, a Synergistic Antibody Cocktail against SARS‑CoV‑2
July 12, 2022
From
ImmunoPrecise Antibodies
Via
Business Wire
Small Cap Biotechnology Companies Release Positive Quarterly Results (IPA, AVIR, LQDA, ABSI, APVO)
May 31, 2022
Via
AB Newswire
Biotech Recovery Accelerates These Companies Benefit (IPA, SIGA, MNKD, INO, CTIC)
May 25, 2022
Via
AB Newswire
IPA’s Subsidiary BioStrand Secures Second VLAIO Research Grant
May 09, 2022
From
ImmunoPrecise Antibodies
Via
Business Wire
IPA’s Advanced PolyTope® TATX-03, a Multi-Antibody Cocktail, Potently Prevents In Vitro Infection of Cells by the Currently Dominant Omicron Sublineage BA.2, in Addition to all Other Variants of Concern
April 20, 2022
From
ImmunoPrecise Antibodies
Via
Business Wire
IPA Completes Acquisition of Belgian Technology Companies BioStrand, BioKey, and BioClue – Adding Artificial Intelligence-Driven Analytics to its Antibody Discovery Capabilities and Offerings
April 14, 2022
From
ImmunoPrecise Antibodies
Via
Business Wire
IPA Announces Agreement to Acquire BioStrand BV – Revolutionizing Biotherapeutics with Methodology to Encode Omics and Power Drug Development with Advanced Artificial Intelligence
March 29, 2022
From
ImmunoPrecise Antibodies
Via
Business Wire
The Daily Biotech Pulse: Pfizer-BioNTech Apply For Authorization Of 3rd Booster Shot, Sanofi-Seagen Strike Cancer Therapy Pact, Iovance Gets Nod For Cancer Study
March 16, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours.
Via
Benzinga
ImmunoPrecise Reports Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2022
March 16, 2022
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.